Butterfly Medical, an Israeli medical-device startup, is focused on enhancing treatment for men dealing with Benign Prostate Hyperplasia (BPH) or enlarged prostate. The company has engineered a fast, simple, and minimally invasive alternative to first-line BPH medication and surgery. Their patented device can be swiftly placed in-office, under local anesthesia, in under 10 minutes without surgical incision, heating, or prostate tissue removal. This novel approach not only aims to provide a long-term, effective solution with minimal side effects but also negates the need for hospitalization or general anesthesia. The early results from clinical trials have been promising, displaying successful prostatic-urethras unblocking with no reported side effects. As of the latest information, Butterfly Medical received Non-Equity Assistance investment from MedTech Innovator on 29 May 2024. The startup, founded in 2014, operates within the Health Care industry and is set to commence further clinical studies in prominent medical centers across Europe. For more details, visit www.butterfly-medical.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
29 May 2024 |
| Series B | $7.00M | 1 |
|
06 Oct 2020 |
| Seed Round | $2.00M | 4 | Paul Merage, Dan Suesskind +2 | 29 Jan 2020 |
| Grant | ILS200.00K | 1 |
|
12 Sep 2019 |
| Venture Round | Unknown | 1 |
|
01 Apr 2016 |
No recent news or press coverage available for Butterfly Medical.
We care about your data, and we'd love to use cookies make your experience better.
